References
- Lutagliata R, Aloe Spiriti M A, Avvisati G, De Gregoris C., Fazi P, Spadea A, Petti M C. Is aggressive chemotherapy the best choice for patients with acute nonlymphocytic leukemia after myelodysplastic syndromes?. Leuk Res 1995; 19: 213–7
- Invernizzi R, Pecci A, Rossi G, Pelizzari A M, Giusto M, Tinelli C., Ascari E. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes. Haematologica 1997; 82: 660–3
- Ruutu T, Hanninen A, Jarventie G, Koistinen P, Koivunen E, Katka K, Nousiainen T, Oksanen K, Pelliniemi T T, Remes K, Timonen T, Volin L, Elonen E. Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine. Leuk Res 1997; 21: 133–8
- Spadea A, Petti M. C., Fazi P, Vegna M. L., Arcese W, Avvisati G, Aloe Spiriti M. A., Istagliata R, Meloni G, Testi A. M., Amadori S, Mandelli F. Mitoxantrone, Etoposide and Intermediate-Dose Ara-C (MEC): an effective Regimen for Poor Risk Acute Myeloid Leukemia. Leukemia 1993; 7: 549–52
- Pogliani E M, Baldicchi L, Pioltelli P, Miccolis I R, Mangia-galli M, Corneo G M. Idarubicin in combination with cytarabine and VP-16 in the treatment of post myelodysplastic syndrome acute myeloblastic leukemia (MDS-AML). Leuk Lymphoma 1995; 19: 473–7
- De Witte T, Suciu S, Boogaerts M, Labar B, Archimbaud E, Runde V, Selleslag D, Zittoun R, Lelie J, Muus P, DeMuynck H, Dardenne M, Willemze R, Gratwohl A, Apperley J. Intensive remission-induction chemotherapy followed by autologous or allogeneic stem cell transplantation (SCT) for high risk MDS and AML secondary to MDS (sAML) in patients < 60 years. A joint study of the EORTC LCG and the EBMT. Blood 1995; 86(Suppl. 1)618a
- Cazzola M, Anderson J E, Ganser A, Hellstrom-Lindberg E. A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica 1998; 83: 910–35
- Wattel E, Solary E, Leleu X, Dreyfus F, Brion A, Jouet J P, Hoang-Ngoc L, Maloisel F, Guerci A, Rochant H, Gratecos N, Casassus P, Janvier M, Brice P, Lepelley P, Fenaux P. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Leukemia 1999; 13: 524–9
- De Witte T, Van Biezen A, Hermans J, Labopin M, Runde V, Or R, Meloni G, Mauri S B, Carella A, Apperley J, Gratwohl A, Laporte J P. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Blood 1997; 90: 3853–7
- Bernasconi C., Alessandrino E P, Bernasconi P, Bonfichi M, Lazzarino M, Canevari A, Castelli G, Brusamolino E, Pag-nucco G, Castagnola C. Randomised clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS. Br J Hae-matol 1998; 102: 678–83
- Wattel E, Solary E, Hecquet B, Caillot D, Ifrah N, Brion A, Mahe B, Milpied N, Janvier M, Guerci A, Rochant H, Cor-donnier C., Dreyfus F, Buzyn A, Hoang-Ngoc L, Stoppa A M, Gratecos N, Sadoun A, Stamatoulas A, Tilly H, Brice P, Maloisel F, Lioure B, Desablens B, Fenaux P. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P-glycoprotein : results of a randomized study. Br J Haematol 1998; 102: 1015–24